Amicus Therapeutics
FOLD
Market cap $1.88B

6.09 USD

-0.21

3.33%

At close Jul 11, 4:00 PM EDT

After hours

6.09

+0.00

0.00%

1 day

-3.33%

5 days

-0.16%

1 month

-0.81%

3 months

-6.02%

6 months

-34.02%

Year to date

-34.59%

1 year

-41.94%

5 years

-59.51%

10 years

-58.57%

About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Employees: 499

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

31% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 86

25% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 5 (+1) [Q1 2025]

3% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 40

1.37% less ownership

Funds ownership: 102.09% [Q4 2024] → 100.72% (-1.37%) [Q1 2025]

1% less funds holding

Funds holding: 285 [Q4 2024] → 281 (-4) [Q1 2025]

12% less capital invested

Capital invested by funds: $2.87B [Q4 2024] → $2.53B (-$347M) [Q1 2025]

36% less call options, than puts

Call options by funds: $3.21M | Put options by funds: $5.05M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

48%

upside

Avg. target

$15.50

155%

upside

High target

$22

261%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

UBS Karl Chalabala	261%upside $22	Buy Maintained	2 May 2025
Goldman Sachs Salveen Richter	48%upside $9	Neutral Maintained	2 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about FOLD published over the past 30 days

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

PHILADELPHIA , July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus") on behalf of the company's shareholders. Year to date, shares of Amicus' stock have declined over 32% in value, to trade at a current price of less than $7.00 per share.

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD).

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

Physician group filed an amicus brief in Chiles v. Salazar defending the right of licensed therapists to offer "conversion therapy" in gender dysphoria.

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

Washington, DC, June 13, 2025 (GLOBE NEWSWIRE) -- The U.S. Supreme Court unanimously reversed the Eleventh U.S. Circuit Court of Appeals' dismissal of Martin v. United States, an Atlanta family's Federal Tort Claims Act (FTCA) suit against the government for a wrong-house raid in 2017.

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Amicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease and is driving consistent revenue growth. Key growth drivers for Galafold include expanding patient reach, new markets, increased market share, and high patient adherence.

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Zacks Investment Research

New Strong Sell Stocks for June 3rd

FOLD, BRCC and VLVLY have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2025.

New Strong Sell Stocks for June 3rd

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured.

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June.

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

See News Rankings

Charts implemented using Lightweight Charts™